Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial Profiling
- PMID: 35490853
- PMCID: PMC9356986
- DOI: 10.1016/j.jtho.2022.04.009
Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial Profiling
Abstract
Introduction: Despite the clinical efficacy of immune checkpoint inhibitors (ICIs) in NSCLC, only approximately 20% of patients remain disease-free at 5 years. Here, we use digital spatial profiling to find candidate biomarker proteins associated with ICI resistance.
Methods: Pretreatment samples from 56 patients with NSCLC treated with ICI were analyzed using the NanoString GeoMx digital spatial profiling method. A panel of 71 photocleavable oligonucleotide-labeled primary antibodies was used for protein detection in four molecular compartments (tumor, leukocytes, macrophages, and immune stroma). Promising candidates were orthogonally validated with quantitative immunofluorescence. Available pretreatment samples from 39 additional patients with NSCLC who received ICI and 236 non-ICI-treated patients with operable NSCLC were analyzed to provide independent cohort validation.
Results: Biomarker discovery using the protein-based molecular compartmentalization strategy allows 284 protein variables to be assessed for association with ICI resistance by univariate analysis using continuous log-scaled data. Of the 71 candidate protein biomarkers, CD66b in the CD45+CD68 molecular compartment (immune stroma) predicted significantly shorter overall survival (OS) (hazard ratio [HR] 1.31, p = 0.016) and was chosen for validation. Orthogonal validation by quantitative immunofluorescence illustrated that CD66b was associated with resistance to ICI therapy but not prognostic for poor outcomes in untreated NSCLC (discovery cohort [OS HR 2.49, p = 0.026], validation cohort [OS HR 2.05, p = 0.046], non-ICI-treated cohort [OS HR 1.67, p = 0.06]).
Conclusions: Using the technique, we have discovered that CD66b expression is indicative of resistance to ICI therapy in NSCLC. Given that CD66b identifies neutrophils, further studies are warranted to characterize the role of neutrophils in ICI resistance.
Keywords: Digital spatial profiling; IHC; Immunohistochemistry; Immunotherapy resistance; NSCLC; Quantitative immunofluorescence.
Copyright © 2022 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
Figures
Comment in
-
CD66b as a prognostic and predictive biomarker in patients with non-small cell lung cancer treated with checkpoint blockade immunotherapy.Transl Cancer Res. 2023 Feb 28;12(2):447-451. doi: 10.21037/tcr-22-2880. Epub 2023 Feb 21. Transl Cancer Res. 2023. PMID: 36915573 Free PMC article. No abstract available.
Similar articles
-
High-throughput transcriptome profiling indicates ribosomal RNAs to be associated with resistance to immunotherapy in non-small cell lung cancer (NSCLC).J Immunother Cancer. 2024 Jun 10;12(6):e009039. doi: 10.1136/jitc-2024-009039. J Immunother Cancer. 2024. PMID: 38857914 Free PMC article.
-
Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non-Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling.Clin Cancer Res. 2020 Aug 15;26(16):4360-4368. doi: 10.1158/1078-0432.CCR-20-0175. Epub 2020 Apr 6. Clin Cancer Res. 2020. PMID: 32253229 Free PMC article.
-
Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.Lung Cancer. 2019 Oct;136:45-51. doi: 10.1016/j.lungcan.2019.08.006. Epub 2019 Aug 14. Lung Cancer. 2019. PMID: 31437663
-
Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade.J Exp Clin Cancer Res. 2024 Mar 16;43(1):82. doi: 10.1186/s13046-024-02969-1. J Exp Clin Cancer Res. 2024. PMID: 38493133 Free PMC article. Review.
-
High-Plex Assessment of Biomarkers in Tumors.Mod Pathol. 2024 Mar;37(3):100425. doi: 10.1016/j.modpat.2024.100425. Epub 2024 Jan 12. Mod Pathol. 2024. PMID: 38219953 Review.
Cited by
-
Macrophage diversity in human cancers: New insight provided by single-cell resolution and spatial context.Heliyon. 2024 Mar 21;10(7):e28332. doi: 10.1016/j.heliyon.2024.e28332. eCollection 2024 Apr 15. Heliyon. 2024. PMID: 38571605 Free PMC article. Review.
-
Unveiling spatial complexity in solid tumor immune microenvironments through multiplexed imaging.Front Immunol. 2024 Mar 19;15:1383932. doi: 10.3389/fimmu.2024.1383932. eCollection 2024. Front Immunol. 2024. PMID: 38566984 Free PMC article.
-
Spatially-resolved transcriptomics reveal macrophage heterogeneity and prognostic significance in diffuse large B-cell lymphoma.Nat Commun. 2024 Mar 8;15(1):2113. doi: 10.1038/s41467-024-46220-z. Nat Commun. 2024. PMID: 38459052 Free PMC article.
-
Genomic alterations associated with pseudoprogression and hyperprogressive disease during anti-PD1 treatment for advanced non-small-cell lung cancer.Front Oncol. 2023 Nov 9;13:1231094. doi: 10.3389/fonc.2023.1231094. eCollection 2023. Front Oncol. 2023. PMID: 38023206 Free PMC article.
-
Advancing Understanding of Non-Small Cell Lung Cancer with Multiplexed Antibody-Based Spatial Imaging Technologies.Cancers (Basel). 2023 Sep 29;15(19):4797. doi: 10.3390/cancers15194797. Cancers (Basel). 2023. PMID: 37835491 Free PMC article. Review.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous